Literature DB >> 10702399

Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells.

S Scarpino1, A Stoppacciaro, F Ballerini, M Marchesi, M Prat, M C Stella, S Sozzani, P Allavena, A Mantovani, L P Ruco.   

Abstract

Tissue distribution of dendritic cells was investigated in eight cases of papillary carcinoma of the thyroid using immunohistochemistry. Most dendritic cells had an immature phenotype (CD1a++, CD11c+, CD40+, CD86-, HLA-DR-) and were located at the invasion edge of the tumor. This pattern of distribution was profoundly different from that of CD68+ macrophages, which were evenly distributed throughout the tumor. The ability of tumor cells to release chemotactic factors active on dendritic cells was investigated in primary cultures of the same cases of papillary carcinoma, and was compared to that of the corresponding normal thyroid cells obtained from the tumor-free contralateral lobe. Chemotactic activity of culture supernatants was tested against dendritic cells in a chemotaxis chamber. It was found that papillary carcinoma cells were active in releasing chemotactic activity, that hepatocyte growth factor (HGF; 100 ng/ml) or interleukin (IL)-1beta (10(3) U/ml) induced a fourfold increase in the amount of chemotactic activity released, and that normal thyroid cells obtained from the same patients were as effective as tumor cells. Characterization of chemokines at RNA level revealed that unstimulated cells contain large amounts of IL-8 and monocyte chemotactic protein (MCP)-1 RNAs, and that stimulation with HGF or IL-1beta induced RNAs for regulated upon activation normal T expressed and secreted (RANTES), macrophage inflammatory protein (MIP)-3alpha, interferon-gamma-inducible protein 10 (IP-10), and, to a lesser extent, MIP-1alpha and MIP-1beta. The possibility that HGF/Met interaction has a biological role in vivo was investigated in serial sections of six tumors immunostained for CD1a+, Met protein, and HGF. It was found that all six tumors were intensely and diffusely positive for Met protein, that HGF staining was present in tumor cells of the advancing edge, and that HGF+/Met+ tumor cell nests were infiltrated by CD1a+ dendritic cells. The foregoing observations are consistent with the possibility that HGF stimulation of Met+ tumor cells is one of the molecular mechanisms involved in the recruitment of dendritic cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702399      PMCID: PMC1876845          DOI: 10.1016/S0002-9440(10)64951-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

Review 1.  The chemokine system: redundancy for robust outputs.

Authors:  A Mantovani
Journal:  Immunol Today       Date:  1999-06

2.  Eosinophilic granuloma of lymph nodes associated with metastatic papillary carcinoma of the thyroid.

Authors:  J B Schofield; N A Alsanjari; J Davis; K A MacLennan
Journal:  Histopathology       Date:  1992-02       Impact factor: 5.087

3.  C-terminal truncated forms of Met, the hepatocyte growth factor receptor.

Authors:  M Prat; T Crepaldi; L Gandino; S Giordano; P Longati; P Comoglio
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

4.  Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid.

Authors:  S Scarpino; A Stoppacciaro; C Colarossi; F Cancellario; A Marzullo; M Marchesi; M Biffoni; P M Comoglio; M Prat; L P Ruco
Journal:  J Pathol       Date:  1999-12       Impact factor: 7.996

5.  Scatter factor is a fibroblast-derived modulator of epithelial cell mobility.

Authors:  M Stoker; E Gherardi; M Perryman; J Gray
Journal:  Nature       Date:  1987 May 21-27       Impact factor: 49.962

6.  Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid.

Authors:  A Zanetti; A Stoppacciaro; A Marzullo; M Ciabatta; F Fazioli; M Prat; P M Comoglio; C D Baroni; L P Ruco
Journal:  J Pathol       Date:  1998-11       Impact factor: 7.996

7.  Dendritic/Langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data.

Authors:  S Schröder; W Schwarz; W Rehpenning; T Löning; W Böcker
Journal:  Am J Clin Pathol       Date:  1988-03       Impact factor: 2.493

8.  Thyroid follicular cells produce interleukin-8.

Authors:  A P Weetman; G L Bennett; W L Wong
Journal:  J Clin Endocrinol Metab       Date:  1992-07       Impact factor: 5.958

9.  Autoregulation by iodine of thyroid protein synthesis: influence of iodine on amino acid transport in cultured thyroid cells.

Authors:  S Filetti; B Rapoport
Journal:  Endocrinology       Date:  1984-04       Impact factor: 4.736

10.  Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy.

Authors:  M L Carcangiu; G Zampi; A Pupi; A Castagnoli; J Rosai
Journal:  Cancer       Date:  1985-02-15       Impact factor: 6.860

View more
  34 in total

Review 1.  Chemokines and dendritic cell traffic.

Authors:  S Sozzani; P Allavena; A Vecchi; A Mantovani
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

2.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Authors:  Rosa Marina Melillo; Maria Domenica Castellone; Valentina Guarino; Valentina De Falco; Anna Maria Cirafici; Giuliana Salvatore; Fiorina Caiazzo; Fulvio Basolo; Riccardo Giannini; Mogens Kruhoffer; Torben Orntoft; Alfredo Fusco; Massimo Santoro
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

3.  Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.

Authors:  Maria Grazia Borrello; Luisella Alberti; Andrew Fischer; Debora Degl'innocenti; Cristina Ferrario; Manuela Gariboldi; Federica Marchesi; Paola Allavena; Angela Greco; Paola Collini; Silvana Pilotti; Giuliana Cassinelli; Paola Bressan; Laura Fugazzola; Alberto Mantovani; Marco A Pierotti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

Review 4.  The immune network in thyroid cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

Review 5.  Chemokines in health and disease.

Authors:  Dayanidhi Raman; Tammy Sobolik-Delmaire; Ann Richmond
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

6.  TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma.

Authors:  C Eloy; J Santos; J Cameselle-Teijeiro; P Soares; M Sobrinho-Simões
Journal:  Virchows Arch       Date:  2012-04-20       Impact factor: 4.064

7.  Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases.

Authors:  Faina Linkov; Robert L Ferris; Zoya Yurkovetsky; Adele Marrangoni; Lyudmila Velikokhatnaya; William Gooding; Brian Nolan; Matthew Winans; Eric R Siegel; Anna Lokshin; Brendan C Stack
Journal:  Proteomics Clin Appl       Date:  2008-10-10       Impact factor: 3.494

8.  Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry.

Authors:  Andrey Bychkov; Vladimir Saenko; Masahiro Nakashima; Norisato Mitsutake; Tatiana Rogounovitch; Alyaksandr Nikitski; Florence Orim; Shunichi Yamashita
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

9.  Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease.

Authors:  Paola Romagnani; Mario Rotondi; Elena Lazzeri; Laura Lasagni; Michela Francalanci; Andrea Buonamano; Stefano Milani; Paolo Vitti; Luca Chiovato; Massimo Tonacchera; Antonio Bellastella; Mario Serio
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

Review 10.  Role of chemokines in tumor growth.

Authors:  Dayanidhi Raman; Paige J Baugher; Yee Mon Thu; Ann Richmond
Journal:  Cancer Lett       Date:  2007-07-12       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.